Webinars and Presentations

Webinars & Presentations

Applications

Virus-like Particles
Cell Based Assays
Cell Therapy
CRISPR/Gene Editing
Gene Editing
Protein Production

Cell Types

Cancer Cell Lines
CHO
Dendritic Cells
HEK293
HSPCs
Insect Cell Lines (S2/Sf9/Sf21)
ion channels
iPSCs
NK Cells
NPCs/NSCs
PBMCs
T Cells

Cell Based Assays

CRISPR/Gene Editing

Gene Editing

Protein Production

CHO

HEK293

Webinar: Beyond Affinity-Antibody Discovery Optimization and Developability Screening from Mammalian Display Libraries

A mammalian antibody display library was constructed using TALEN-mediated integration enabled by Maxcyte STx electroporation. Improved antibody variants exhibited optimal biophysical properties, including high solubility, low aggregation and low T cell immune response, all of which could help to avoid costly, late-stage, clinical failures of protein drugs. Webinar presented October 19, 2022

Cell Therapy

CRISPR/Gene Editing

HSPCs

NK Cells

Presentation: Which industry partner should I collaborate with? A scientists’ journey to implementing an innovative technology

With our best-in-class delivery system, our team of scientific experts helps our collaborators unlock the potential of their products by solving development and commercialization challenges. This session will feature success stories from two of our client advocates, Dr. Jonathan Yen and Dr. Alicja Copik. Their talks will showcase MaxCyte’s focus on high-performance cellular editing and our outstanding technical support to enable our customers to use a single unifying technology, from concept to clinic. Presentation recorded during ASGCT Annual meeting May 16, 2022.

Cell Therapy

CRISPR/Gene Editing

Keratinocytes

Presentation: Scalable Electroporation of Adult Keratinocytes with Multiplexed CRISPR

In the past, engineered keratinocyte-based cell therapies have been limited by the lack of efficient transfection methods for adult keratinocytes. Here we aimed to develop a GMP-compliant, scalable cell engineering process using the MaxCyte^®cell electroporation platform to transfect neonatal and adult primary keratinocytes from four distinct anatomical locations. Delivery of multiple CRISPR RNPs in a single electroporation achieved highly efficient, multiplexed gene editing in a simple, adaptable process.

Cell Therapy

CRISPR/Gene Editing

Presentation: Enabling Scalable Cell Engineering Using the MaxCyte® to ExPERT^TM Electroporation Platform

In this presentation you will learn:
-High-performance engine accelerating the clinical translation of next generation cell therapies.
-Twenty years of experience in primary cell transfection, protein production, and genome engineering.
-Continued expansion of cell therapy partnerships with leading industry innovators and multiple programs currently in clinical trials.
-Trusted by the top academic, translational and commercial groups for their R&D, PD and MFG work.

Cell Therapy

Gene Editing

TCR/CAR T

CAR T

T Cells

Presentation: Next-Generation DNA NanoVectors – an alternative Vector Platform for the safe, rapid and persistent manufacture of recombinant T cells for Autologous T Cell Immunotherapy

• Best in class DNA Vector that combine mitotic stability with low immunogenicity • Efficiently produced in bacterial cells at high yield and purity without post-processing • Provide robust transgene expression in every cell and model system available • Efficacy comparable to state-of-the-art clinically utilized vectors with short, efficient and economical manufacturing time

Cell Based Assays

CRISPR/Gene Editing

T Cells

Development of a genome-wide CRISPR screen in CD4+ T cells to identify drug targets for immune-mediated inflammatory diseases

Apr 7, 2021 – Dr. Ricky Trigg – Immune-mediated inflammatory diseases (IMIDs) are a group of disorders characterized by tissue inflammation as a result of dysregulated immune responses. This webinar will showcase the development of a genome-wide CRISPR screen in primary T cells to identify drug targets for IMIDs, and will cover key areas of workflow optimization, including lentiviral transduction, Cas9 electroporation in bulk cell populations, and fluorescence-activated cell sorting.

Protein Production

CHO

BioProcess International: Ask the Expert Webcast

Employing a transient transfection strategy using Flow Electroporation enabled efficient, cost-effective evaluation of HIV vaccine candidates accelerating the therapeutic product into animal studies months ahead of schedule.

Cell Therapy

CRISPR/Gene Editing

HSPCs

Correction of the Sickle Cell Disease Mutation with CRISPR/Cas9

October 15th, 2020 – Dr. Mark DeWitt – Project Scientist at the University of California, Los Angeles – Sickle Cell Disease (SCD), one of the world’s most common genetic disorders, causes anemia and progressive multiorgan damage that typically shortens lifespan by decades; currently there is no broadly applicable curative therapy. A universal curative therapy for SCD would address a critical unmet medical need in the United States and worldwide. During this webinar, Dr. Mark DeWitt will discuss the development of a CRISPR/Cas9-based strategy to correct the mutation in CD34+ HSPCs harvested from SCD patients.

CRISPR/Gene Editing

Gene Editing

Primary Cells

TCR/CAR T

Webinar: Scalable Manufacturing and Nanovesicle Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP Compliant Cell Engineering Platform

CRISPR-Cas9 has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from viral vectors in an in vivo context may cause unwanted off-target activity and immunogenicity. To overcome these safety issues, a system was recently developed for transient delivery of CRISPR-Cas9 ribonucleoprotein (RNP), recruiting Cas9 protein by chemically-induced dimerization and sgRNA via a viral RNA packaging signal into extracellular nanovesicles. Webinar presented by Peter Gee, MaxCyte, Inc., Field Application Scientist on September 17, 2020.

Cell Therapy

CRISPR/Gene Editing

NK Cells

PBMCs

T Cells

Webinar: Overview of a Flexible, Clinically Adaptable, Non-viral Approaches to CAR TCR Methodologies

Abstract: In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies that demonstrate the successful use of MaxCyte’s clinically validated, scalable electroporation system in the pre-clinical and clinical scale engineering of resting and activated T cells using a mesothelin specific CARmRNA; in the enhancement of NK cell cytotoxicities against B cell malignancies using an antiCD19 CAR mRNA; in the transposon (Piggybac and Sleeping Beauty) based gene delivery for manufacture of CAR-T cells ; and finally in the gene editing of T cells for improving the efficacy of a TCR immunotherapy. August 04, 2020.